{"nctId":"NCT00911144","briefTitle":"Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine","startDateStruct":{"date":"2009-06-11"},"conditions":["Infections, Streptococcal"],"count":450,"armGroups":[{"label":"Synflorix Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)","Biological: GSK Biologicals' Hiberix™"]},{"label":"Prevenar Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Wyeth-Lederle's Prevenar™","Biological: GSK Biologicals' Hiberix™"]}],"interventions":[{"name":"GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)","otherNames":["Pneumococcal vaccine GSK1024850A"]},{"name":"Wyeth-Lederle's Prevenar™","otherNames":[]},{"name":"GSK Biologicals' Hiberix™","otherNames":["Hib"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female between, and including, 12-18 months of age at the time of booster vaccination.\n* Subjects for whom the investigator believes that their parent(s)/ guardian(s) can and will comply with the requirements of the protocol.\n* Subjects who received three doses of pneumococcal conjugate vaccine in study NCT00680914.\n* Written informed consent obtained from the parent(s)/guardian(s) of the child/ward.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the vaccination, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.\n* Administration of immunoglobulins and/or any blood products within three months preceding the vaccination or planned administration during the study period.\n* Administration of any pneumococcal and/or Hib vaccine since the end of study NCT00680914.\n* Planned administration/administration of a vaccine not allowed by the study protocol during the period starting 1 month (30 days) before the administration of the booster dose of the study vaccines (Visit 1) and up to the follow-up visit (Visit 2) with the exception of vaccines included in the Korean routine immunization which can be given at least one week before the administration of the study vaccines or after study end.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* History of reactions or allergic disease likely to be exacerbated by any component of the study vaccines.\n* Known hypersensitivity to any component of the study vaccines including anaphylactic reactions following the administration of the study vaccines.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Tympanic or axillary/ oral temperature \\>= 37.5°C or rectal temperature \\>= 38.0°C. A temperature greater than or equal to these cut-offs warrants deferral of the vaccination pending recovery of the subject.\n* Acute disease at the time of enrolment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Grade 3 Adverse Events","description":"Grade 3 adverse events are severe symptoms that prevent normal, everyday activities.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (equal to or above 37.5 degrees Celsius), irritability and loss of appetite.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Adverse Events","description":"An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any \"solicited\" symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events","description":"Serious adverse events are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Vaccine Pneumococcal Serotypes","description":"Concentrations of antibodies are measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations expressed as microgram per milliliter (ug/mL).\n\nVaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.77","spread":null},{"groupId":"OG001","value":"12.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.51","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null},{"groupId":"OG001","value":"7.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.39","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.99","spread":null},{"groupId":"OG001","value":"12.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.73","spread":null},{"groupId":"OG001","value":"22.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.14","spread":null},{"groupId":"OG001","value":"14.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.89","spread":null},{"groupId":"OG001","value":"4.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":null},{"groupId":"OG001","value":"14.81","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes","description":"Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.\n\nVaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"363.7","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1058.0","spread":null},{"groupId":"OG001","value":"3717.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233.9","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"546.5","spread":null},{"groupId":"OG001","value":"3826.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5467.5","spread":null},{"groupId":"OG001","value":"1038.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1707.5","spread":null},{"groupId":"OG001","value":"5204.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1814.6","spread":null},{"groupId":"OG001","value":"3958.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"607.9","spread":null},{"groupId":"OG001","value":"1723.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1284.5","spread":null},{"groupId":"OG001","value":"277.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2702.9","spread":null},{"groupId":"OG001","value":"29918.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"Concentrations of antibodies are measured by 22F-inhibition ELISA and are presented as geometric mean concentrations expressed as microgram per milliliter.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null},{"groupId":"OG001","value":"2.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":null},{"groupId":"OG001","value":"0.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196.1","spread":null},{"groupId":"OG001","value":"1415.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Protein D (PD)","description":"Concentrations of antibodies are presented as geometric mean concentrations expressed as Enzyme-Linked Immuno-Sorbent Assay (ELISA) units per milliliter (EU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1288.9","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Polyribosyl-ribitol-phosphate (PRP)","description":"Concentrations of antibodies are presented as geometric mean concentrations expressed as microgram per milliliter.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.970","spread":null},{"groupId":"OG001","value":"99.738","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":335},"commonTop":["Redness at the injection site","Irritability","Pain at the injection site","Swelling at the injection site","Loss of appetite"]}}}